NEW YORK, Sept 19 – Spotfire, a developer of analytics software used by pharmaceutical and biotechnology companies, is considering an initial public offering on the Nasdaq next year.

Chris Ahlberg, Spotfire’s CEO, said the Cambridge, Mass.-based company expects to use money from an IPO for general business purposes. He declined to say how much the company hopes to raise.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.